Vinorelbine
- PDF / 169,165 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 90 Downloads / 153 Views
1 S
Neutropenia: case report In a multinational retrospective study involving 30 patients, a patient [age and sex not stated] was described, who developed grade 3 neutropenia while receiving vinorelbine for metastatic non small cell lung cancer (NSCLC). The patient, who had metastatic NSCLC, received unspecified first line chemotherapy and second line immunotherapy; however, the disease continued to progress. Consequently, the patient started receiving third line chemotherapy with metronomic oral vinorelbine 30mg three times a week (on Monday, Wednesday and Friday), given 30 minutes after a meal. The patient also received antiemetic therapy with ondansetron 1 hour before vinorelbine. However, the patient developed transitory grade 3 neutropenia secondary to vinorelbine [duration of treatment to reaction onset not stated]. Gebbia V, et al. Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: A retrospective analysis. 803518215 Ecancermedicalscience 14: 29 Sep 2020. Available from: URL: http://doi.org/10.3332/ECANCER.2020.1113
0114-9954/20/1832-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 28 Nov 2020 No. 1832
Data Loading...
